ENYO Pharma Completes Series C Financing and Advances ALPESTRIA-1 Phase 2 Study in Alport Syndrome

ENYO Pharma, a biotechnology company located in Lyon, France, has announced the successful progress of its Phase 2 ALPESTRIA-1 trial. This clinical-stage firm specializes in developing FXR agonists aimed at treating severe kidney diseases. The ongoing trial examines Vonafexor, a selective oral FXR agonist, in 26 patients with Alport syndrome, a genetic kidney disease for which no therapy has been approved. The results of this trial are anticipated in the fourth quarter of 2025.

The ALPESTRIA-1 study commenced in mid-2024 across four countries—the United States, France, Spain, and Germany—after receiving Orphan Drug Designation from both the FDA and EMA. The trial includes a 24-week regimen of increasing doses, followed by a 12-week observation period without treatment.

In tandem with the trial's progress, ENYO has successfully completed its Series C financing round, securing an additional €6 million from Vesalius Biocapital IV, thus bringing the total raised to €32 million. This new funding extends ENYO's operating funds through the latter half of 2026 and supports the launch of two new clinical initiatives. The first involves a proof-of-concept trial for patients with Chronic Kidney Disease (CKD) grade 3 and concurrent F2/F3 Metabolic Associated Steatohepatitis (MASH), leveraging promising renal outcomes from the previous Phase 2 LIVIFY study. The second initiative is a pharmacokinetic/pharmacodynamic comparison of Vonafexor with its analog EYP651 in healthy subjects.

Additionally, ENYO plans to broaden its preclinical research portfolio, particularly in Autosomal Dominant Polycystic Kidney Disease (ADPKD), where Vonafexor could potentially offer a novel disease-modifying treatment.

Dr. Jacky Vonderscher, CEO of ENYO, expressed satisfaction with ALPESTRIA-1's progress and welcomed Vesalius Biocapital to its group of investors. Dr. Jean-Christophe Renondin has also joined ENYO’s board, further strengthening the company's governance. The investment from Vesalius Biocapital will accelerate the development of ENYO's FXR agonist pipeline, targeting both rare and more common kidney diseases. ENYO and Vesalius share a belief in the transformative potential of Vonafexor and EYP651 in treating inflammation- and fibrosis-driven renal conditions.

Dr. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV, expressed enthusiasm about supporting ENYO as it advances Vonafexor and EYP651 into further clinical development phases. He emphasized the significant need for novel treatments in kidney diseases like Alport Syndrome and CKD and highlighted Vonafexor's potential to make a substantial impact on patients' lives. Renondin looks forward to collaborating with ENYO's leadership to propel this promising therapeutic forward.

ENYO Pharma is committed to enhancing the quality of life for patients with both rare and common kidney diseases by developing proprietary drug candidates aimed at avoiding end-stage renal disease and the need for dialysis or transplantation. Since its inception, ENYO has gathered extensive clinical data through nine completed studies involving approximately 400 subjects.

Vesalius Biocapital, a venture capital firm specializing in life sciences, has been investing in later-stage companies in drug development and digital health since 2007. Vesalius Biocapital IV, launched in June 2023, focuses on first and best-in-class European life science companies. The firm is dedicated to fostering innovation driven by scientific research, supporting ambitious entrepreneurs, and exploring investment opportunities within its portfolio.